Adaptive Biotechnologies Strengthens Expertise and Diversity of Board of Directors with Appointments of Leslie Trigg and Kate...
March 17 2021 - 4:05PM
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial
stage biotechnology company that aims to translate the genetics of
the adaptive immune system into clinical products to diagnose and
treat disease, today announced the appointments of Leslie Trigg and
Katey Owen, Ph.D. to its Board of Directors effective immediately.
The collective commercial and scientific expertise of these
industry leaders will strengthen Adaptive’s ability to execute
against its open-ended growth story. The company also announced
that Eric Dobmeier and David Goel will retire from the Board after
long-standing tenures.
“I am excited to welcome Leslie and Katey to our
Board during this pivotal period of commercial expansion and
scientific innovation. Diversity of thought, perspectives, and
experience is essential as we seek to transform clinical care in
many diagnostic and therapeutic areas,” said Chad Robins, chief
executive officer of Adaptive Biotechnologies. “I’d like to thank
Eric and David for the invaluable roles they played to help
position Adaptive as a leader in immune medicine, as well as their
guidance during the transition from a private to public
company.”
Leslie’s expertise will be instrumental in the
commercial adoption of Adaptive’s products into the clinical
setting. She has served as Chief Executive Officer of Outset
Medical since 2014, where she has pioneered disruptive technology
transformation in the kidney dialysis space. With rapidly growing
revenue across several market segments, Outset completed a
successful public offering in 2020. Prior to Outset Medical, Leslie
held executive commercial strategy roles at numerous med tech
companies that went public or were acquired, including Pro-Duct
Health, FoxHollow, AccessClosure, and Lutonix. She received her
undergraduate degree from Northwestern University and her MBA from
the Haas School of Business, UC Berkeley.
Katey’s expertise in developing late-stage
biologics and vaccines at the Gates Foundation and Merck will help
guide Adaptive’s expansion into new therapeutic areas. As Director
at the Bill & Melinda Gates Foundation, Dr. Owen has end-to-end
responsibility for investments in diseases that impact a billion
people on the planet. She also facilitates regular interaction
between Bill Gates and the CEOs of pharmaceutical organizations to
achieve global health goals. Prior to joining the
pharmaceutical industry, she carried out academic research on
influenza at the National Institute for Medical Research in Mill
Hill, London. She earned her Ph.D. in molecular virology from
Purdue University.
About
Adaptive Biotechnologies Adaptive
Biotechnologies is a commercial-stage biotechnology company
focused on harnessing the inherent biology of the adaptive immune
system to transform the diagnosis and treatment of disease. We
believe the adaptive immune system is nature’s most finely tuned
diagnostic and therapeutic for most diseases, but the inability to
decode it has prevented the medical community from fully leveraging
its capabilities. Our proprietary immune medicine platform reveals
and translates the massive genetics of the adaptive immune system
with scale, precision and speed to develop products in life
sciences research, clinical diagnostics and drug discovery. We have
three commercial products and a robust clinical pipeline to
diagnose, monitor and enable the treatment of diseases such as
cancer, autoimmune conditions and infectious diseases. Our goal is
to develop and commercialize immune-driven clinical products
tailored to each individual patient. For more information, please
visit adaptivebiotech.com and follow us
on www.twitter.com/adaptivebiotech.
Forward Looking Statements This
press release contains forward-looking statements that are based on
management's beliefs and assumptions and on information currently
available to management. All statements contained in this release
other than statements of historical fact are forward-looking
statements, including statements regarding our ability to develop,
commercialize and achieve market acceptance of our current and
planned products and services, our research and development efforts
and other matters regarding our business strategies, use of
capital, results of operations and financial position and plans and
objectives for future operations.
In some cases, you can identify forward-looking
statements by the words "may," "will," "could," "would," "should,"
"expect," "intend," "plan," "anticipate," "believe," "estimate,"
"predict," "project," "potential," "continue," "ongoing" or the
negative of these terms or other comparable terminology, although
not all forward-looking statements contain these words. These
statements involve risks, uncertainties and other factors that may
cause actual results, levels of activity, performance or
achievements to be materially different from the information
expressed or implied by these forward-looking statements. These
risks, uncertainties and other factors are described under "Risk
Factors," "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in the documents
we file with the Securities and Exchange Commission from time to
time. We caution you that forward-looking statements are based on a
combination of facts and factors currently known by us and our
projections of the future, about which we cannot be certain. As a
result, the forward-looking statements may not prove to be
accurate. The forward-looking statements in this press release
represent our views as of the date hereof. We undertake no
obligation to update any forward-looking statements for any reason,
except as required by law.
ADAPTIVE MEDIA:Beth
Keshishian917-912-7195media@adaptivebiotech.com
ADAPTIVE INVESTORS:Karina
Calzadilla201-396-1687Carrie Mendivil, Gilmartin
Groupinvestors@adaptivebiotech.com
Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart
From Apr 2023 to Apr 2024